-
1
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
-
(2009)
J Clin Oncol
, vol.27
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
Hartmann, J.T.4
Aparicio, J.5
De Braud, F.6
-
2
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer
-
DOI 10.1056/NEJMoa033025
-
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.4
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
Bets, D.7
Mueser, M.8
Harstrick, A.9
Verslype, C.10
Chau, I.11
Van Cutsem, E.12
-
3
-
-
78149250536
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
-
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4697-4705
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
Tabernero, J.4
Burkes, R.5
Barugel, M.6
-
4
-
-
34147103678
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer
-
DOI 10.1200/JCO.2006.08.1620
-
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64. (Pubitemid 46797944)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.13
, pp. 1658-1664
-
-
Van Cutsem, E.1
Peeters, M.2
Siena, S.3
Humblet, Y.4
Hendlisz, A.5
Neyns, B.6
Canon, J.-L.7
Van Laethem, J.-L.8
Maurel, J.9
Richardson, G.10
Wolf, M.11
Amado, R.G.12
-
5
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Köhne, C.H.2
Hitre, E.3
Zaluski, J.4
Chang Chien, C.R.5
Makhson, A.6
-
6
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M, Van CE, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
Van, C.E.4
Siena, S.5
Freeman, D.J.6
-
7
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
De Schutter, J.4
Biesmans, B.5
Fountzilas, G.6
-
8
-
-
33646228635
-
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
-
Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
-
(2006)
Cancer Res
, vol.66
, pp. 3992-3995
-
-
Lièvre, A.1
Bachet, J.B.2
Le Corre, D.3
Boige, V.4
Landi, B.5
Emile, J.F.6
-
9
-
-
77957205044
-
Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
-
Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010;46:2781-7.
-
(2010)
Eur J Cancer
, vol.46
, pp. 2781-2787
-
-
Qiu, L.X.1
Mao, C.2
Zhang, J.3
Zhu, X.D.4
Liao, R.Y.5
Xue, K.6
-
10
-
-
0023748414
-
Genetic alterations during colorectal-tumor development
-
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
-
(1988)
N Engl J Med
, vol.319
, pp. 525-532
-
-
Vogelstein, B.1
Fearon, E.R.2
Hamilton, S.R.3
Kern, S.E.4
Preisinger, A.C.5
Leppert, M.6
-
11
-
-
58749102224
-
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice
-
Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008;13:1270-5.
-
(2008)
Oncologist
, vol.13
, pp. 1270-1275
-
-
Santini, D.1
Loupakis, F.2
Vincenzi, B.3
Floriani, I.4
Stasi, I.5
Canestrari, E.6
-
12
-
-
65549143792
-
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
-
Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Crüger D, et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009;20:879-84.
-
(2009)
Ann Oncol
, vol.20
, pp. 879-884
-
-
Garm Spindler, K.L.1
Pallisgaard, N.2
Rasmussen, A.A.3
Lindebjerg, J.4
Andersen, R.F.5
Crüger, D.6
-
13
-
-
76049098292
-
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases
-
Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 790-799
-
-
Baldus, S.E.1
Schaefer, K.L.2
Engers, R.3
Hartleb, D.4
Stoecklein, N.H.5
Gabbert, H.E.6
-
14
-
-
77954668198
-
Acquired KRAS mutations during progression of colorectal cancer metastases: Possible implications for therapy and prognosis
-
Bouchahda M, Karaboué A, Saffroy R, Innominato P, Gorden L, Guettier C, et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 2010;66:605-9.
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, pp. 605-609
-
-
Bouchahda, M.1
Karaboué, A.2
Saffroy, R.3
Innominato, P.4
Gorden, L.5
Guettier, C.6
-
15
-
-
51349141191
-
Circulating mutant DNA to assess tumor dynamics
-
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.
-
(2008)
Nat Med
, vol.14
, pp. 985-990
-
-
Diehl, F.1
Schmidt, K.2
Choti, M.A.3
Romans, K.4
Goodman, S.5
Li, M.6
-
16
-
-
41649114743
-
Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer
-
Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 2008;263:170-81.
-
(2008)
Cancer Lett
, vol.263
, pp. 170-181
-
-
Frattini, M.1
Gallino, G.2
Signoroni, S.3
Balestra, D.4
Lusa, L.5
Battaglia, L.6
-
17
-
-
77956467360
-
Cell-free DNA in the blood as a solid tumor biomarker - A critical appraisal of the literature
-
Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - A critical appraisal of the literature. Clin Chim Acta 2010;411:1611-24.
-
(2010)
Clin Chim Acta
, vol.411
, pp. 1611-1624
-
-
Jung, K.1
Fleischhacker, M.2
Rabien, A.3
-
19
-
-
16344382732
-
Persistence of K-ras mutations in plasma after colorectal tumor resection
-
Lindforss U, Zetterquist H, Papadogiannakis N, Olivecrona H. Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 2005;25:657-61. (Pubitemid 40470078)
-
(2005)
Anticancer Research
, vol.25
, Issue.1 B
, pp. 657-661
-
-
Lindforss, U.1
Zetterquist, H.2
Papadogiannakis, N.3
Olivecrona, H.4
-
20
-
-
84857088615
-
Improved classification of epithelial ovarian cancer. Results of 3 Danish cohorts
-
Steffensen KD, Waldstrøm W, Grove A, Lund B, Pallisgaard N, Jakobsen A. Improved classification of epithelial ovarian cancer. Results of 3 Danish cohorts. Int J Gynecol Cancer 2011;21:1592-600.
-
(2011)
Int J Gynecol Cancer
, vol.21
, pp. 1592-1600
-
-
Steffensen, K.D.1
Waldstrøm, W.2
Grove, A.3
Lund, B.4
Pallisgaard, N.5
Jakobsen, A.6
-
21
-
-
78049435890
-
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
-
Thierry A, Mouliere F, Gongore C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010;38:6159-75.
-
(2010)
Nucleic Acids Res
, vol.38
, pp. 6159-6175
-
-
Thierry, A.1
Mouliere, F.2
Gongore, C.3
Ollier, J.4
Robert, B.5
Ychou, M.6
-
22
-
-
79952006628
-
All about KRAS for clinical oncological practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer
-
Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, et al. All about KRAS for clinical oncological practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 2011;37:221-33.
-
(2011)
Cancer Treat Rev
, vol.37
, pp. 221-233
-
-
Linardou, H.1
Briasoulis, E.2
Dahabreh, I.J.3
Mountzios, G.4
Papadimitriou, C.5
Papadopoulos, S.6
-
23
-
-
67650366758
-
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer
-
Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.Clin Cancer Res 2009;15:4508-13.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4508-4513
-
-
Yen, L.C.1
Yeh, Y.S.2
Chen, C.W.3
Wang, H.M.4
Tsai, H.L.5
Lu, C.Y.6
-
24
-
-
22244472992
-
Poor survival associated with the BRAF V600E mutation in microsatelite-stable colon cancers
-
Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatelite-stable colon cancers. Cancer Res 2005;14:6063-9.
-
(2005)
Cancer Res
, vol.14
, pp. 6063-6069
-
-
Samowitz, W.S.1
Sweeney, C.2
Herrick, J.3
Albertsen, H.4
Levin, T.R.5
Murtaugh, M.A.6
-
25
-
-
56649084987
-
Comprehensive biostatistical analysis of CgP island methylator phenotype in colorectal cancer using an large population-based sample
-
Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CgP island methylator phenotype in colorectal cancer using an large population-based sample. PLoS One 2008;11:e3698.
-
(2008)
PLoS One
, vol.11
-
-
Nosho, K.1
Irahara, N.2
Shima, K.3
Kure, S.4
Kirkner, G.J.5
Schernhammer, E.S.6
|